Gene Logic Drug Candidate Shows Positive In Vivo Test Results

  
    
  
  
    
      Gene Logic Inc. (NASDAQ: GLGC) announced today that GL1001, the company’s 
      clinical-stage drug candidate, showed indications of efficacy at 
      relevant doses in in vivo testing for inflammatory bowel disease 
      (IBD). Based on the in vivo test results and market opportunities 
      in IBD, the Company is seeking a partner for the clinical development of 
      GL1001.
    
    
      Gene Logic discovered the new potential therapeutic use for GL1001 using 
      its Drug Repositioning Platform, a diverse set of drug evaluation 
      technologies the Company uses to assess drug candidates for potential 
      utility across a wide spectrum of disease indications. GL1001 was found 
      to suppress the induction of a key inflammatory mediator both in vivo 
      and in vitro. The data were also supported by analysis of Gene 
      Logic’s proprietary gene expression database, 
      BioExpress®. Gene Logic performed the work 
      under an agreement with Millennium Pharmaceuticals and subsequently 
      acquired certain exclusive rights to GL1001 for commercial development.
    
    
      IBD is a chronic health problem characterized by inflammation and 
      swelling in the digestive tract, leading to ulcers and bleeding. 
      Symptoms may include cramping, abdominal pain, and diarrhea. There are 
      two main types of inflammatory bowel disease: ulcerative colitis and 
      Crohn’s disease, and the conditions affect as 
      many as 1 million Americans.
    
    
      Gene Logic’s Drug Repositioning Program seeks 
      to find alternative development paths for drug candidates with good 
      safety records that have been de-prioritized or discontinued in clinical 
      trials. The program offers pharmaceutical partners a novel approach to 
      bolster their pipelines with high-quality drug candidates that 
      originated from their own R&D efforts. The program can also yield 
      proprietary drug candidates for the Company when a partner chooses not 
      to develop a compound for a use identified by the Company.
    
    
      Charles L. Dimmler, III, Gene Logic CEO and President, commented, “Our 
      in vivo tests provide data that indicate GL1001 has the potential 
      to treat IBD. We also view this in vivo proof-of-concept as 
      further evidence that our Drug Repositioning Platform has the potential 
      to yield clinically interesting drug development opportunities that may 
      be validated in industry-standard models of efficacy. Our next step will 
      be to secure the right partner to pursue a clinical development strategy 
      for GL1001. At the same time, we are working with our existing drug 
      repositioning partners to discover new uses for their discontinued drug 
      candidates in other therapeutic areas.”
    
    
      Gene Logic Overview
    
    
      Gene Logic is transforming into a pharmaceutical development company 
      through partnerships with pharmaceutical companies. Our partners provide 
      Gene Logic with access to their drug candidates that have been assessed 
      as safe in human clinical trials but discontinued for other reasons. 
      Gene Logic applies its drug indication platform to find new therapeutic 
      uses for the drug candidates. Gene Logic expects to receive milestone 
      payments and royalties on drug candidates that our partners choose to 
      develop based on the indications we find or, if the partner elects not 
      to pursue such new indications, Gene Logic may receive ownership and 
      development rights.
    
    
      Gene Logic has also developed proprietary genomics databases and 
      services to enable customers worldwide to discover and prioritize drug 
      targets, identify biomarkers, predict toxicity and understand mechanisms 
      of toxicity, and obtain insights into the efficacy of specific 
      compounds. We continue to offer customers these services and licenses to 
      the databases. Such databases, services and expertise are also a vital 
      part of our drug indication platform. Following consideration of various 
      strategic alternatives for its Genomics Division, the Company is 
      concentrating its efforts on investigating the possibility of a sale of 
      all or parts of its Genomics business while continuing to serve new and 
      existing Genomics customers.
    
    
      Founded in 1994, Gene Logic is headquartered in Gaithersburg, Md., with 
      additional research and development facilities in Cambridge, Mass. The 
      Company currently has about 150 employees worldwide. For more 
      information, visit www.genelogic.com 
      or call toll-free – 1/800/GENELOGIC.